Symbiosis Pharmaceutical Services
Stirling, United Kingdom
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
76.8
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (8)
Quick Facts: Symbiosis Pharmaceutical Services
- Signal Score
- 76.8/100 (as of 2026-09-07)
- Quality Compliance
- 100.0/100
- Headquarters
- Stirling, United Kingdom
- Modalities
- Cell Therapy
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Symbiosis Pharmaceutical Services
Pure-play CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-01-31)
MHRA GMP Certificates8 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
53.0
Profile-based capacity assessment
Symbiosis Pharmaceutical Services FDA Inspection History
2025-01
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-01-31 |
Symbiosis Pharmaceutical Services Limited
Stirling
Facility-linked
|
Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Oct 07, 2026
Attribution not established
(1)
These records are excluded from this company’s established evidence
because their attribution is unresolved. This describes an evidence-linking
limitation, not an assessment of the underlying regulatory findings.
| Source | Establishment named by the regulator | Location | Identifier |
|---|---|---|---|
| MHRA GMP certificate | COX PHARMACEUTICAL LIMITED | STIRLING | — |
Source records retained verbatim · attribution not established
Symbiosis Pharmaceutical Services MHRA GMP Compliance 8 certificates
2025-02
2025-02
2025-02
2025-02
2024-08
2024-08
2023-09
2023-09
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 40211 Insp IMP 40211/405290-0019[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/37423042-0004[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/405290-0020[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/37423042-0005[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/33209260-0005[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/33209260-0006[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [V] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Oct 07, 2026
Frequently Asked Questions About Symbiosis Pharmaceutical Services
How many FDA inspections does Symbiosis Pharmaceutical Services have on record?
CDMO Signal tracks 1 FDA inspection for Symbiosis Pharmaceutical Services, sourced from the FDA inspection database. See the full inspection history above.
Has Symbiosis Pharmaceutical Services received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Symbiosis Pharmaceutical Services.
Does Symbiosis Pharmaceutical Services hold EMA or MHRA GMP certificates?
CDMO Signal tracks 8 MHRA GMP certificates for Symbiosis Pharmaceutical Services.
What is Symbiosis Pharmaceutical Services's CDMO Signal Score?
Symbiosis Pharmaceutical Services has a Signal Score of 77/100, based on quality, operations, financial stability, and capacity data.
Evaluating Symbiosis Pharmaceutical Services for a manufacturing program?
Use the free AI matchmaker to compare Symbiosis Pharmaceutical Services against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Ori Biotech
London, United Kingdom
Signal Score: 78.1
CAR-T, Cell Therapy
eXmoor Pharma
Bristol, United Kingdom
Signal Score: 78.1
Cell Therapy, AAV
HiTech Health
London, United Kingdom
Signal Score: 76.8
Cell Therapy
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy, AAV
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 91.1
CAR-T, Cell Therapy